The global Induced Pluripotent Stem Cells Production Market size is estimated to reach USD 1.76 billion by 2028, registering a CAGR of 8.0% over the forecast period, according to a new report by Grand View Research, Inc. Lonza, Axol Biosciences Ltd., Evotec, Hitachi Ltd., Merck KGaA are some of the key players in this industry. The market is driven by technological advancements in induced pluripotent cell manufacturing, rising awareness about the therapeutic potency of such cells, and extensive research on the development of regenerative medicine using induced pluripotent cells. The ability of iPS cells to differentiate with maximum diversity has been one of the key drivers propelling its usage in gene and cell therapy applications.
The high therapeutic potential of induced pluripotent stem cells (iPSCs) has expanded its applications in the past few years making significant contributions to the market revenue. For instance, extensive research activities are being carried out on iPSC-derived exosomes, organoid-generation for drug testing, and iPSC-based vaccines. iPS cells have paved the way for the commercialization of innovative cell-based therapies in regenerative medicine owing to their ability to propagate indefinitely. In addition, iPS cells have extended their applications in regenerative medicines and therapies as they effectively avoid the ethical limitations of human embryonic stem cells and lower the risks of immune rejection, contamination, & infection.
Degenerative eye disorders are the most common targeted disorders in induced pluripotent cell-based clinical trials, along with cardiac syndromes, such as myocardial ischemia and heart failure, followed by spinal cord injury and neuropathies - Parkinson’s disease, and thrombocytopenia from aplastic anemia. Moreover, the rising popularity of automated platforms for iPS cells production is further contributing to the industry growth. The automated production platform offers an ideal chance of reliable reproducibility of cells in addition to cost reduction and increases throughput.
Acknowledging the profitable opportunities posed by the market, key players in the induced pluripotent stem cells generation industry are focusing on mergers & acquisitions to strengthen their presence. In March 2021, Axol Biosciences signed a merger agreement with Censo Biotechnology. This entity is set to become one of the leading providers of products and services in the iPSC-based immune cell, neuroscience, and cardiac modeling for the drug discovery and screening market.
Related Press Release@ Induced Pluripotent Stem Cells Production Market Report
Induced Pluripotent Stem Cells Production Market Report Highlights
- Widespread potential applications of iPS cells in drug development and discovery has resulted in the segment’s dominance in 2020
- On the other hand, regenerative medicine is expected to be the fastest-growing application segment over the forecast period due to the high usage of iPSCs in treating a number of injuries and degenerative diseases
- Automated platforms for iPSCs production have gained immense demand owing to the rising requirement for reproducible large-scale stem cell and differentiated progeny production, with minimum variation
- Research and academic institutes are projected to register the fastest CAGR from 2021 to 2028 due to a rise in the number of collaborations between researchers
- These collaborations are largely targeted towards finding out the potential application of iPSCs in stem cell biology, translational research, clinical investigation of diseases
- Favorable government initiatives, high R&D expenditure, availability of advanced research facilities & skilled professionals, and active policies pertaining to cell therapies have contributed to the dominance of the North American regional market in 2020
- The key players are engaged in exploring iPSC therapy to its highest potential across different emerging applications, contributing to the market growth
- In February 2021, Evotec entered into a partnership with the Medical Center Hamburg-Eppendorf. The partnership aims to develop iPSC- based cell therapy for the treatment of heart failure
- Under this partnership, Evotec and UKE will leverage their mutual strength for the development of iPSC- based therapy approach with the help of Engineered Heart Tissue for curing heart failure
